Identification of a Novel
SHANK2
exome sequencing (ES)
language impairment
neurodevelopmental disorder
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
14 04 2022
14 04 2022
Historique:
received:
14
02
2022
revised:
06
03
2022
accepted:
12
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Genetic defects in the SHANK2 gene, encoding for synaptic scaffolding protein, are associated with a variety of neurodevelopmental conditions, including autism spectrum disorders and mild to moderate intellectual disability. Until now, limited patient clinical descriptions have been published. Only 13 unrelated patients with SHANK2 pathogenic variations or microdeletions have been reported worldwide. By Exome Sequencing, we identified a de novo stop-gain variant, c.334C>T, p.(Gln112*), in an Italian patient with a neurodevelopmental disorder. The patient (9 years old) presented the following facial features: a flat profile, thick eyebrows, long eyelashes, a bulbous nasal tip and a prominent columella, retracted ears, dental anomalies. The patient showed speech delay and mild neuromotor delay but not autism spectrum disorder. In conclusion, this patient with a novel pathogenic variant in SHANK2 enlarges the phenotypic spectrum of SHANK2-mutated patients and demonstrates that the severity of SHANK2-associated disorders is highly variable.
Identifiants
pubmed: 35456494
pii: genes13040688
doi: 10.3390/genes13040688
pmc: PMC9025881
pii:
doi:
Substances chimiques
Nerve Tissue Proteins
0
SHANK2 protein, human
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Références
J Neurochem. 2002 Jun;81(5):903-10
pubmed: 12065602
PLoS Genet. 2014 Sep 04;10(9):e1004580
pubmed: 25188300
Nat Genet. 2014 Sep;46(9):944-50
pubmed: 25086666
Cell. 2017 Oct 19;171(3):710-722.e12
pubmed: 28965761
Neurosci Biobehav Rev. 2021 Oct;129:117-132
pubmed: 34339708
Mol Psychiatry. 2021 Nov;26(11):6482-6504
pubmed: 34021263
Nature. 2015 Mar 12;519(7542):223-8
pubmed: 25533962
Annu Rev Neurosci. 2001;24:1-29
pubmed: 11283303
Genes (Basel). 2021 Jul 08;12(7):
pubmed: 34356069
Nature. 2012 Apr 04;485(7397):246-50
pubmed: 22495309
J Neurosci Res. 2022 Apr;100(4):970-978
pubmed: 35114017
Mol Syndromol. 2011 Jan;1(4):176-184
pubmed: 21373257
Hum Mol Genet. 2012 Jan 15;21(2):344-57
pubmed: 21994763
Nat Neurosci. 2019 Apr;22(4):556-564
pubmed: 30911184
Nature. 2014 Jul 17;511(7509):344-7
pubmed: 24896178
Neuron. 2013 Apr 10;78(1):8-27
pubmed: 23583105
Genome Med. 2017 May 30;9(1):43
pubmed: 28554332
Eur J Med Genet. 2020 Dec;63(12):104072
pubmed: 32987185
Am J Med Genet A. 2017 Mar;173(3):801-805
pubmed: 28211979
Nature. 2017 Feb 23;542(7642):433-438
pubmed: 28135719
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Trends Cell Biol. 2011 Oct;21(10):594-603
pubmed: 21840719
Nature. 2010 Jul 15;466(7304):368-72
pubmed: 20531469
Pediatrics. 2011 Jun;127(6):1034-42
pubmed: 21606152
Mol Brain. 2020 Apr 6;13(1):54
pubmed: 32252796
J Mol Neurosci. 2021 Jan;71(1):1-8
pubmed: 32897530
Mol Autism. 2020 Oct 30;11(1):87
pubmed: 33126897
Nature. 2014 Nov 13;515(7526):216-21
pubmed: 25363768
Nat Genet. 2015 Jun;47(6):582-8
pubmed: 25961944
Hum Mutat. 2019 Jun;40(6):801-815
pubmed: 30763456
Mol Autism. 2018 Dec 13;9:64
pubmed: 30564305
PLoS Genet. 2012 Feb;8(2):e1002521
pubmed: 22346768
Nature. 2012 Apr 04;485(7397):237-41
pubmed: 22495306
Front Mol Neurosci. 2021 Nov 26;14:773571
pubmed: 34899182
Nat Genet. 2010 Jun;42(6):489-91
pubmed: 20473310